A randomized controlled trial of prednisone in Alzheimer's disease

Paul S. Aisen, K. L. Davis, J. D. Berg, K. Schafer, K. Campbell, R. G. Thomas, M. F. Weiner, Martin Farlow, M. Sano, M. Grundman, L. J. Thal

Research output: Contribution to journalArticle

405 Citations (Scopus)

Abstract

Background: Laboratory and epidemiologic studies suggest that anti- inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of low to moderate dose prednisone was found to suppress peripheral inflammatory markers without adverse effects in subjects with AD. Methods: We conducted a randomized, placebo-controlled multicenter trial to determine whether prednisone treatment slowed the rate of cognitive decline in AD. The active treatment regimen consisted of an initial dose of 20 mg of prednisone daily for 4 weeks tapered to a maintenance dose of 10 mg daily for I year, followed by gradual withdrawal during an additional 16 weeks. The primary outcome measure was the 1-year change in the cognitive subscale of the AD Assessment Scale. Results A total of 138 subjects were randomized to the drug and placebo groups. There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only. Subjects treated with prednisone showed behavioral decline compared with those in the placebo group. Conclusion: A low-dose regimen of prednisone is not useful in the treatment of AD.

Original languageEnglish
Pages (from-to)588-593
Number of pages6
JournalNeurology
Volume54
Issue number3
StatePublished - Feb 8 2000

Fingerprint

Prednisone
Alzheimer Disease
Randomized Controlled Trials
Placebos
Therapeutics
Immunosuppressive Agents
Multicenter Studies
Epidemiologic Studies
Anti-Inflammatory Agents
Outcome Assessment (Health Care)
Pharmaceutical Preparations

Keywords

  • AD
  • Anti-inflammatory therapy
  • Glucocorticoids
  • Randomized controlled trial

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., ... Thal, L. J. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Neurology, 54(3), 588-593.

A randomized controlled trial of prednisone in Alzheimer's disease. / Aisen, Paul S.; Davis, K. L.; Berg, J. D.; Schafer, K.; Campbell, K.; Thomas, R. G.; Weiner, M. F.; Farlow, Martin; Sano, M.; Grundman, M.; Thal, L. J.

In: Neurology, Vol. 54, No. 3, 08.02.2000, p. 588-593.

Research output: Contribution to journalArticle

Aisen, PS, Davis, KL, Berg, JD, Schafer, K, Campbell, K, Thomas, RG, Weiner, MF, Farlow, M, Sano, M, Grundman, M & Thal, LJ 2000, 'A randomized controlled trial of prednisone in Alzheimer's disease', Neurology, vol. 54, no. 3, pp. 588-593.
Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology. 2000 Feb 8;54(3):588-593.
Aisen, Paul S. ; Davis, K. L. ; Berg, J. D. ; Schafer, K. ; Campbell, K. ; Thomas, R. G. ; Weiner, M. F. ; Farlow, Martin ; Sano, M. ; Grundman, M. ; Thal, L. J. / A randomized controlled trial of prednisone in Alzheimer's disease. In: Neurology. 2000 ; Vol. 54, No. 3. pp. 588-593.
@article{65f2f8f859b543c29fa9747730e48218,
title = "A randomized controlled trial of prednisone in Alzheimer's disease",
abstract = "Background: Laboratory and epidemiologic studies suggest that anti- inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of low to moderate dose prednisone was found to suppress peripheral inflammatory markers without adverse effects in subjects with AD. Methods: We conducted a randomized, placebo-controlled multicenter trial to determine whether prednisone treatment slowed the rate of cognitive decline in AD. The active treatment regimen consisted of an initial dose of 20 mg of prednisone daily for 4 weeks tapered to a maintenance dose of 10 mg daily for I year, followed by gradual withdrawal during an additional 16 weeks. The primary outcome measure was the 1-year change in the cognitive subscale of the AD Assessment Scale. Results A total of 138 subjects were randomized to the drug and placebo groups. There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only. Subjects treated with prednisone showed behavioral decline compared with those in the placebo group. Conclusion: A low-dose regimen of prednisone is not useful in the treatment of AD.",
keywords = "AD, Anti-inflammatory therapy, Glucocorticoids, Randomized controlled trial",
author = "Aisen, {Paul S.} and Davis, {K. L.} and Berg, {J. D.} and K. Schafer and K. Campbell and Thomas, {R. G.} and Weiner, {M. F.} and Martin Farlow and M. Sano and M. Grundman and Thal, {L. J.}",
year = "2000",
month = "2",
day = "8",
language = "English",
volume = "54",
pages = "588--593",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A randomized controlled trial of prednisone in Alzheimer's disease

AU - Aisen, Paul S.

AU - Davis, K. L.

AU - Berg, J. D.

AU - Schafer, K.

AU - Campbell, K.

AU - Thomas, R. G.

AU - Weiner, M. F.

AU - Farlow, Martin

AU - Sano, M.

AU - Grundman, M.

AU - Thal, L. J.

PY - 2000/2/8

Y1 - 2000/2/8

N2 - Background: Laboratory and epidemiologic studies suggest that anti- inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of low to moderate dose prednisone was found to suppress peripheral inflammatory markers without adverse effects in subjects with AD. Methods: We conducted a randomized, placebo-controlled multicenter trial to determine whether prednisone treatment slowed the rate of cognitive decline in AD. The active treatment regimen consisted of an initial dose of 20 mg of prednisone daily for 4 weeks tapered to a maintenance dose of 10 mg daily for I year, followed by gradual withdrawal during an additional 16 weeks. The primary outcome measure was the 1-year change in the cognitive subscale of the AD Assessment Scale. Results A total of 138 subjects were randomized to the drug and placebo groups. There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only. Subjects treated with prednisone showed behavioral decline compared with those in the placebo group. Conclusion: A low-dose regimen of prednisone is not useful in the treatment of AD.

AB - Background: Laboratory and epidemiologic studies suggest that anti- inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of low to moderate dose prednisone was found to suppress peripheral inflammatory markers without adverse effects in subjects with AD. Methods: We conducted a randomized, placebo-controlled multicenter trial to determine whether prednisone treatment slowed the rate of cognitive decline in AD. The active treatment regimen consisted of an initial dose of 20 mg of prednisone daily for 4 weeks tapered to a maintenance dose of 10 mg daily for I year, followed by gradual withdrawal during an additional 16 weeks. The primary outcome measure was the 1-year change in the cognitive subscale of the AD Assessment Scale. Results A total of 138 subjects were randomized to the drug and placebo groups. There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only. Subjects treated with prednisone showed behavioral decline compared with those in the placebo group. Conclusion: A low-dose regimen of prednisone is not useful in the treatment of AD.

KW - AD

KW - Anti-inflammatory therapy

KW - Glucocorticoids

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=0034620538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034620538&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 588

EP - 593

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -